We are live on ! Find out more
CGON icon

CG Oncology

233 hedge funds and large institutions have $6.59B invested in CG Oncology in 2026 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 85 increasing their positions, 71 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

660% more call options, than puts

Call options by funds: $187M | Put options by funds: $24.5M

20% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 71

15% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 33

10% more funds holding in top 10

Funds holding in top 10: 10 → 11 (+1)

2% more funds holding

Funds holding: 229 → 233 (+4)

2% more capital inflows, than outflows

Capital inflows: $462M | Capital outflows: $453M

1.45% less ownership

Funds ownership: 106.37% → 104.92% (-1.4%)

Holders
233
Holders Change
+4
Holders Change %
+1.75%
% of All Funds
2.83%
Holding in Top 10
11
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+10%
% of All Funds
0.13%
New
38
Increased
85
Reduced
71
Closed
33
Calls
$187​M
Puts
$24.5​M
Net Calls
+$162​M
Net Calls Change
-⁠$10.6​M

CGON Hedge Fund Activity: Q3 2026 in Review

233 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in CG Oncology (CGON) for Q3 2026, worth a combined $6.59B — down 1.1% from $6.66B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new CGON positions and 33 closed out — a net gain of 5 holders — while 85 added to existing stakes and 71 trimmed.

The largest buyer was Hood River Capital Management, opening a new position worth an estimated $64.9M. The largest seller was OrbiMed, exiting entirely with an estimated $69.1M sold.

  • 233 institutional investors held CG Oncology (CGON) as of Q3 2026, up from 229 in Q2 2026.
  • Funds reported $6.59B of CG Oncology stock for Q3 2026, down 1.1% quarter-over-quarter.
  • 38 funds opened new CG Oncology positions in Q3 2026 and 33 closed out, a net change of +5 holders.
  • The largest CG Oncology buyer in Q3 2026 was Hood River Capital Management, an estimated $64.9M added.
  • The largest CG Oncology seller in Q3 2026 was OrbiMed, an estimated $69.1M sold.

Based on aggregated 13F filings for Q3 2026.